Business Context and Reporting Period
Company: MyMD Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2024
Reporting Period: Specific event date of June 17, 2024.
This filing reports a material modification to the rights of security holders regarding the Company's Series G Convertible Preferred Stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure amendments.
Material Changes
- Amendment to Certificate of Designations: On June 17, 2024, the Company entered into an Amendment Agreement with Required Holders of its Series G Convertible Preferred Stock.
- Authorized Share Increase: The number of authorized shares of Series G Convertible Preferred Stock was increased from 8,950 to 12,826,273.
- Purpose: The increase was authorized to ensure a sufficient number of shares are available for the payment of dividends "in kind" (additional shares of Preferred Stock) as permitted under Section 3 of the Certificate of Designations.
- Effective Date: The Certificate of Amendment was filed with the Secretary of State of Delaware on June 17, 2024, and became effective immediately upon filing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard legal disclaimer that the description of the Certificate of Amendment is qualified by reference to the full text of the document filed as Exhibit 3.1.
Investor Verification Checklist
- Verify the full text of the Certificate of Amendment (Exhibit 3.1) to understand all terms of the "in kind" dividend provision.
- Review the original Securities Purchase Agreement dated May 20, 2024, to understand the initial terms of the Series G Convertible Preferred Stock.
- Confirm the impact of the increased authorized share count on potential future dilution of common stockholders.
- Check subsequent filings for any actual issuance of "in kind" dividends under the new authorization.